Two AUA program highlights will feature Blue Light Cystoscopy with Cysview® study data:
- On Sunday, May 5th, Dr. Sanjay Das will present the study, “Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis”
The study, known as BRAVO (Bladder Cancer Recurrence Analysis in Veterans and Outcomes), is a retrospective, propensity score matched analysis that evaluated oncologic outcomes following BLC® compared to WLC alone in patients from the Veterans Affairs (VA) Healthcare System.
(PD48: Bladder Cancer: Non-invasive III,
Sunday, May 5, 2024 1:00 PM to 3:00 PM, room 304A)
- Monday, May 6th, Poster presentation by Dr. Hailong Hu: “Blue Light Cystoscopy versus White Light Cystoscopy for the Detection of Bladder Cancer using modern HD 4K equipment: An Analysis of Pivotal Trial and Real-World Data”. This pooled meta-analysis includes data from a randomized clinical trial and a supporting real-world evidence study conducted in China.
(MP71: Bladder Cancer: Non-invasive IV,
Monday, May 6, 2024 9:30 AM to 11:30 AM, room 302B)
Source: Photocure ASA. (2024). Bladder Cancer: Pivotal Trial Results and New Real-World Evidence, to Be Presented at AUA 2024, Demonstrate Improved Diagnostic and Clinical Outcomes with Blue Light Cystoscopy [Press release]. https://photocure.com/newsletters/news-from-photocure-4808020?utm_source=email&utm_medium=email_campaign&utm_campaign=newsletter.